BOSTON and ROCHESTER, N.Y., June 9, 2014 (GLOBE NEWSWIRE) -- Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., has inaugurated its new VivaScan™ skin imaging procedure for the general public at NIDIskin (Non-Invasive Diagnostic Imaging of the Skin) Consulting, located at 8383 Wilshire Boulevard in Beverly Hills, California.
VivaScan is a safe, painless and simple procedure that provides cellular images of the skin. Once the images have been captured, they are analyzed by a physician who determines a diagnosis and recommendation on treatment. Using a handheld confocal microscope, VivaScan produces clear, cellular images that reveal a level of detail equivalent to analyzing a tissue sample in a laboratory. Since VivaScan does not cut into the skin the way biopsy does, it can make unlimited repeat scans of the same skin lesion over time.
Babar K. Rao, M.D., Director of NIDIskin Consulting, said, "I am extremely pleased that our facility in Beverly Hills is hosting the initial rollout of VivaScan, an important option for patients who are concerned about a skin lesion but who are apprehensive about needing a biopsy, especially for a lesion that may turn out to be benign. The accessibility, ease and speed of a VivaScan procedure makes it a compelling and attractive new diagnostic tool for patients and doctors alike."
VivaScan, which was developed by Caliber Imaging & Diagnostics (Caliber I.D.), can take cellular level images of entire lesions, layer by layer, at and below the surface of the skin, and can help physicians diagnose most skin diseases and disorders. Since there is no cutting of the skin involved, there is also no possibility of infection or scarring. Obtaining an image takes just a few minutes. A physician can make a determination at the bedside, or the images can be diagnosed remotely through Caliber I.D.'s VivaNet® Telepathology system.
L. Michael Hone, Chief Executive Officer of Caliber I.D., said, "Skin cancer is the most prevalent cancer in the United States, with an estimated 3.5 million new cases each year. Until recently, the only way to diagnose this condition was by visual inspection, followed by an invasive and painful biopsy if suspect areas were found. Laboratory results could take days, and visible areas of the skin could be scarred. Clearly, there is a significant need for a more accurate, less invasive way to assess skin cancers and benign lesions. We believe VivaScan offers this option to the general public on a large scale for the very first time."
Joseph R. Williams, Vice President of Global Marketing at Caliber I.D., added, "The rollout of VivaScan at NIDIskin Consulting in Beverly Hills marks just the first step in what we foresee as a wide-scale healthcare initiative. We expect that the VivaScan procedure's appeal to the general public might eventually lead to its being offered by skin care facilities across the United States and internationally."
About Caliber Imaging & Diagnostics
Caliber Imaging & Diagnostics' proprietary, cutting-edge VivaScope® system is a disruptive, noninvasive point-of-care platform imaging technology with numerous applications in dermatology, surgery and research. FDA 510(k) cleared, VivaScope has regulatory approval in most major markets. With 78 issued and pending patents worldwide, VivaScope has the potential to significantly improve outcomes and reduce costs. The VivaScan™ procedure, which utilizes the VivaScope for dermatological examination, allows physicians to detect cancerous lesions that appear benign, and reduces the need for expensive, painful and time-consuming biopsies, which show no malignancy approximately 70% of the time. VivaScope also has significant applications in testing and analysis in the academic, medical and therapeutic research markets. For more information about Caliber I.D. and its products, please visit www.caliberid.com.
VivaScope® and VivaNet® are registered trademarks of Caliber Imaging & Diagnostics.
VivaScan™ is a trademark of Caliber Imaging and Diagnostics.
This press release contains "forward looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including the statements regarding the potential for future product revenue growth and financial performance. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.
CONTACT: Company Contact: Richard Christopher Chief Financial Officer (617) 348-9821 email@example.com Investor Relations Contact: LHA Kim Sutton Golodetz (212) 838-3777 firstname.lastname@example.org Public Relations Contacts: Dian Griesel Int'l. Susan Forman or Laura Radocaj (212) 825-3210 email@example.com firstname.lastname@example.orgSource:Caliber Imaging & Diagnostics, Inc.